6 Cardiology Headlines You Missed in June 2026

Despite being a comparatively quiet month, June nonetheless produced a handful of significantly impactful clinical data and drug approvals. The US Food and Drug Administration (FDA) accepted and granted Priority Review to mavacamten in adolescents, as well as approved olezarsen for severe hypertriglyceridemia. On the conference side, an updated analysis of VESALIUS-CV has revealed evolocumab’s ability to reduce cardiovascular events. At the same time, new guidelines from the American College of Cardiology and the American Heart Association provide clinicians with a more direct approach to diagnosing and managing cardiovascular-metabolic-kidney (CKM) syndrome.

The HCPLive editorial team has collected 6 of the most impactful headlines from June 2026 below – catch up on any cardiology news you may have missed over the last month:

FDA News

FDA Approves Olezarsen (Tryngolza) for Severe Hypertriglyceridemia

On June 24, 2026, 6 days ahead of its scheduled PDUFA date, the FDA announced its approval of olezarsen as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adult patients with severe hypertriglyceridemia. This decision makes olezarsen the first therapy approved for this specific indication. The once-monthly, self-administered subcutaneous drug will be available in the US at some point in July, according to the announcement by parent company Ionis.

Mavacamten sNDA Gets FDA Priority Review for Adolescent Obstructive HCM

On June 1, 2026, Bristol Myers Squibb announced the FDA’s acceptance of a supplemental new drug application (sNDA) for mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). A PDUFA target action date of September 30, 2026, was assigned on the same day. Additionally, the FDA granted mavacamten’s sNDA Priority Review status for patients aged 12 to <18 years. If approved, this application would expand mavacamten’s current indication beyond adults with symptomatic oHCM.

Trial Results

VESALIUS-CV: Evolocumab Reduces Cardiovascular Events in Patients With High-Risk Diabetes

A new subgroup analysis of VESALIUS-CV, presented at the American Diabetes Association Scientific Sessions 2026, has indicated evolocumab’s efficacy in reducing cardiovascular events in patients with high-risk diabetes mellitus. Of the 12,257 patients enrolled in the original trial, 6002 were included in the analysis, which saw that 3-point major adverse cardiovascular event (MACE) risk reduced by 29% in evolocumab recipients after the 4.6 median years of follow-up.

AHA, ACC Issue First-Ever Clinical Guideline for Cardiovascular-Kidney-Metabolic Syndrome

Almost 90% of adults in the US have ≥1 risk factor for cardiovascular-kidney-metabolic (CKM) syndrome – given these statistics, alongside the rising prevalence of several of these risk factors, the American Heart Association and American College of Cardiology have officially released the first-ever clinical guideline for CKM syndrome. Excess weight in the abdomen was identified as a key driver for both disease development and progress.

Conference Insights

The Value of Albuminuria in Heart Failure Risk Assessment, with Javed Butler, MD, MBA

Albuminuria, measured with the urine albumin-to-creatinine ratio, has reemerged as a biomarker at the intersection of kidney and cardiovascular risk. In a discussion with HCPLive, Javed Butler, MD, MPH, president of the Baylor Scott & White Research Institute and a heart failure trialist, provided clinicians with advice on when to act on an elevated ratio, if albuminuria warrants a major shift in heart failure risk assessment, and whether it could become a cornerstone of therapeutic monitoring in future trials.

Q&A: Cardiometabolic Care Cascade Failure Points, with Rishi Wadhera, MD, MPP, MPhil

In a discussion with HCPLive, Rishi Wadhera, MD, MPP, MPhil, associate professor of medicine at Harvard Medical School and associate director of the Smith Center for Outcomes Research at Beth Israel Deaconess Medical Center, explained the shortcomings that still exist in the cardiometabolic care cascade. Despite widespread awareness campaigns, almost 40% of adults with hypertension aged 20-44 years are unaware of their diagnosis. Additionally, groundbreaking treatments like SGLT2 inhibitors and GLP-1 RAs are only reaching 1 in 5 eligible patients.